Dr Reddy's Labs Faces Profit Decline Amidst North American Challenges

Dr Reddy's Laboratories Ltd reported an 86% drop in Q4 profit due to reduced generics sales in North America. Consolidated revenue fell by 12%, while Indian and European generics sales saw growth. The company aims to strengthen its business through cost efficiency and strategic portfolio optimization.

Drugmaker Dr Reddy's Laboratories Ltd has announced an 86% decrease in consolidated profit for the fourth quarter ending March 31, 2026, largely due to diminished generics sales in North America.

The company reported a consolidated total revenue from operations of Rs 7,546.4 crore, down from Rs 8,528.4 crore in the same period last year. North American generics revenue dropped 51%, contrasting with India and Europe, where generics sales grew by 20% and 14%, respectively.

Co-Chairman & MD, G V Prasad expressed confidence in strengthening core business through cost efficiencies and portfolio optimization, while the board proposed a final dividend of Rs 8 per equity share for FY26, pending shareholder approval.